Crossmark

Cost-Effectiveness of Targeted Next-Generation Sequencing for Diagnosing Pre-XDR and XDR Tuberculosis in Rifampicin-Resistant Patients Across High-Burden Settings

Crossref DOI link: https://doi.org/10.1016/j.arbres.2026.04.007

Published Print: 2026-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Fekadu, Ginenus

Tolossa, Tadesse

Labata, Busha Gamachu

Fite, Meseret Belete

Feyissa, Tesfaye Regassa

Yi, Xinyao

Chan, Sze Chai

Chen, Yanya

Arpa, Cemre

Bekele, Firomsa

Gao, Lan

Chaiyakunapruk, Nathorn

Yang, Lianping

Jeldu, Meseret

Chen, Shanquan

Siegel, Martin

Ming, Wai-Kit
License Information

Text and Data Mining valid from 2026-10-01

Text and Data Mining valid from 2026-10-01

Version of Record valid from 2026-04-24
More Information

This article is maintained by: Elsevier

Article Title: Cost-Effectiveness of Targeted Next-Generation Sequencing for Diagnosing Pre-XDR and XDR Tuberculosis in Rifampicin-Resistant Patients Across High-Burden Settings

Journal Title: Archivos de Bronconeumología

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.arbres.2026.04.007

Content Type: article

Copyright: © 2026 The Author(s). Published by Elsevier España, S.L.U. on behalf of SEPAR.

Document is current

Any future updates will be listed below